Table 1.
Clinicopathological features of patients with diffuse large B‐cell lymphoma (DLBCL), grouped according to Epstein–Barr virus (EBV) positivity
| EBV‐positive DLBCL (n = 23) | EBV‐negative DLBCL (n = 43) | P‐value | |
|---|---|---|---|
| Clinical features | |||
| Median age, years (range) | 77 (2–88) | 71 (30–91) | 0.66 |
| Male : female | 1.6:1.0 | 1.0:1.0 | 0.50 |
| Clinical stage | |||
| I–II (%) | 14/23 (61) | 24/40 (60) | 0.84 |
| III–IV (%) | 9/23 (39) | 16/40 (40) | |
| Median LDH, IU/L (range) | 290 (141–1255) | 243.5 (158–970) | 0.31 |
| Median sIL2R, U/mL (range) | 1932 (340–11000) | 1483.5 (165–25400) | 0.63 |
| Anemia | 8/11 (73) | 13/31 (42) | 0.16 |
| Three‐year survival rate, % | 38.9 | 72.2 | 0.04 |
| Immunohistochemical features | |||
| CD5‐positive (%) | 0/15 (0) | 5/43 (12) | 0.40 |
| Median Ki‐67 labelling index (range) | 49.95 (20.5–76.1) | 60 (27.9–83.7) | 0.08 |
| ABC type (%) | 15/18 (83) | 22/43 (51) | 0.04 |
| GCB type (%) | 3/18 (17) | 21/43 (49) | |
| Treatment | |||
| R‐CHOP or R‐CHOP‐like regimen (%) | 8/13 (62) | 23/32 (72) | |
| CHOP or CHOP‐like regimen (%) | 2/13 (15) | 6/32 (19) | |
| Radiotherapy (%) | 0/13 (0) | 1/32 (3) | |
| Other (%) | 3/13 (23) | 2/32 (6) | |
Bold indicates statistical significance (P < 0.05). ABC, activated B‐cell‐like; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; GCB, germinal centre B‐cell‐like; LDH, lactate dehydrogenase; R, rituximab; sIL2R, soluble interleukin‐2 receptor.